Kimberly-Clark Acquires Kenvue

Suzano and Kimberly-Clark Form $3.4B Global Tissue Joint Venture

June 5, 2025

Consumer Products

Suzano and Kimberly-Clark announced the creation of a $3.4 billion global tissue joint venture operating in more than 70 countries. Suzano will acquire a 51% stake at closing, paying Kimberly-Clark $1.734 billion in cash, while Kimberly-Clark holds 49% and retains U.S. consumer tissue and professional businesses.

Alcon Acquires EYSUVIS and INVELTYS Commercial Portfolio from Kala Pharmaceuticals

May 23, 2022

Pharmaceuticals

Alcon Inc. agreed to acquire the commercial portfolio and related intellectual property for EYSUVIS and INVELTYS from Kala Pharmaceuticals for an upfront payment of $60 million, with Kala eligible for future commercial milestone payments. The asset sale allows Alcon to expand its ophthalmic drug franchises while enabling Kala to focus on its pipeline (KPI-012) and extend its cash runway.

Cooper Consumer Health Acquires Viatris' Over-the-Counter Business

July 3, 2024

Pharmaceuticals

Cooper Consumer Health has completed the acquisition of the Over-the-Counter (OTC) business of Viatris Inc., following regulatory approvals and worker council consultations. The deal brings more than 200 brands (including Betadine, Saugella, Armolipid and CB12), two manufacturing sites in Mérignac (France) and Confienza (Italy) and an R&D centre in Monza (Italy) into Cooper's platform, doubling Cooper's revenues to approximately €1.2bn.

Nestlé Acquires The Bountiful Company's Core Vitamin Brands for $5.75B

August 9, 2021

Food & Beverage

Nestlé (via Nestlé Health Science) agreed to acquire the core vitamin and supplement brands of The Bountiful Company from KKR and Carlyle for $5.75 billion, integrating brands such as Nature's Bounty, Solgar, Puritan's Pride and Osteo Bi‑Flex into its NHSc portfolio. The deal (expected/closed in H2 2021) brings roughly 4,000–4,500 employees into Nestlé Health Science and establishes Nestlé as a global leader in vitamins, minerals and nutritional supplements across mass retail, specialty retail and e‑commerce.

Fresenius Kabi Acquires Ivenix

March 31, 2022

Medical Devices

Ivenix, Inc. has entered into a definitive agreement to be acquired by Fresenius Kabi for an upfront payment of $240 million plus additional milestone payments. The deal brings Ivenix's next-generation infusion pump technology and software together with Fresenius Kabi's IV fluids and infusion therapy portfolio to create a comprehensive infusion offering and accelerate U.S. commercial expansion.

Eli Lilly and Company to Acquire Ventyx Biosciences

January 8, 2026

Pharmaceuticals

Eli Lilly and Company has entered into a definitive agreement to acquire Ventyx Biosciences for approximately $1.2 billion. The deal values Ventyx at $14.00 per share in cash and is expected to close in the first half of 2026, subject to shareholder and regulatory approvals.